Related references
Note: Only part of the references are listed.Marginal Effects-Quantifying the Effect of Changes in Risk Factors in Logistic Regression Models
Edward C. Norton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Rural Counties With Majority Black Or Indigenous Populations Suffer The Highest Rates Of Premature Death In The US
Carrie E. Henning-Smith et al.
HEALTH AFFAIRS (2019)
Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
Yoon Soo Hah et al.
SCIENTIFIC REPORTS (2019)
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
Daniel J. Khalaf et al.
EUROPEAN UROLOGY (2019)
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Megan E. V. Caram et al.
JAMA NETWORK OPEN (2019)
Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer
Megan E. V. Caram et al.
UROLOGY PRACTICE (2019)
Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Megan E. V. Caram et al.
BMC CANCER (2018)
Structural racism and health inequities in the USA: evidence and interventions
Zinzi D. Bailey et al.
LANCET (2017)
Racial Disparities in Cancer Care in the Veterans Affairs Health Care System and the Role of Site of Care
Cleo A. Samuel et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Black Patients More Likely Than Whites To Undergo Surgery At Low-Quality Hospitals In Segregated Regions
Justin Dimick et al.
HEALTH AFFAIRS (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System
Leah L. Zullig et al.
MILITARY MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer
Henry K. Tsai et al.
CANCER (2006)
Race and surgical mortality in the United States
FL Lucas et al.
ANNALS OF SURGERY (2006)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
